\
&
Contact us
\
&
Contact us
Starts in 2 weeks from now
LocationRoyal Institute for Cultural Heritage (KIK-IRPA), Brussels
ProgrammesThis event hosted by the Royal Institute for Cultural Heritage (KIK-IRPA) in Brussels is an initiative from three projects funded by Horizon Europe: MOXY, GreenArt, and GoGreen united in a Green Cluster for Science and Conservation Research.
This strategic policy meeting brings together Green Cluster Project participants, European Commission policymakers, and leading practitioners in conservation, cultural heritage, sustainability, and industrial stakeholders to explore how green conservation can be more effectively integrated into European cultural heritage policy. The day aligns the work of the Green Cluster with European policy and industry, highlighting opportunities for integration, implementation, and support based on green innovation and technological developments.
Fore more information on this event and programme please visit the webpage of the event.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
